Healthcare Industry News: Elaprase
News Release - June 29, 2006
Shire's DAYTRANA(TM), First Transdermal Medication for Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Children, Now Available in PharmaciesPHILADELPHIA, Pennsylvania, June 29 (HSMN NewsFeed) -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced the availability of DAYTRANA (methylphenidate transdermal system), the first and only transdermal medication approved to treat the symptoms of Attention Deficit Hyperactivity Disorder (ADHD). The ADHD patch DAYTRANA (http://www.daytrana.com), a once daily transdermal formulation of methylphenidate, is now available in retail pharmacies in 10 mg, 15 mg, 20 mg and 30 mg dosage strengths and is offered in trade packages of 10 patches for titration and 30 patches for ongoing therapy. The U.S. Food and Drug Administration (FDA) approved DAYTRANA on April 6, 2006.
ADHD affects approximately 7.8 percent of all school-age children, or about 4.4 million children in the U.S. ADHD is considered the most commonly diagnosed psychiatric disorder in children and adolescents. ADHD is a neurological brain disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable age and maturity. If untreated, ADHD can acutely affect a child's life, leading to problems with family members, friends, sports, after-school activities and academics.
DAYTRANA was developed by Noven Pharmaceuticals, Inc., and combines the active ingredient, methylphenidate, with Noven's patented DOT Matrix(tm) transdermal technology. This transdermal delivery system was designed to provide continuous release of medication throughout the day. The patch is designed to stay on during the normal daily activities of a child such as swimming, exercising or bathing.
"Since the effect of the medication in DAYTRANA starts to decrease upon patch removal, the ADHD patch allows parents, at the direction of the physician, to vary the duration of effect of the medication up to the recommended nine-hour wear time," said Oscar Bukstein, associate professor of psychiatry, University of Pittsburgh School of Medicine. "Because not all children with ADHD are the same and because a child's schedule may vary from day to day, parents and patients may benefit from the individualized management of a patient's ADHD symptoms that DAYTRANA provides. DAYTRANA is a valuable new tool in the treatment of ADHD."
DAYTRANA Significantly Controls ADHD symptoms
Data from phase II and phase III clinical trials demonstrated statistically significant improvements in the primary and secondary endpoints analyzed for children aged 6-12 years treated with DAYTRANA compared to children treated with placebo.
The phase II analog classroom study included 79 children with ADHD. The patch was worn for nine hours, and significant efficacy was demonstrated at the first time point measured, two hours after patch application, and throughout the day for 12 hours. The participants treated with DAYTRANA demonstrated statistically significant improvement over placebo on the measures tested. Behavior, which was measured using the Swanson, Kotkin, Agler, M-Flynn, and Pelham-Deportment (SKAMP-D) scale, in which higher ratings reflect greater impairment, was improved with DAYTRANA overall (mean score 3.2 for DAYTRANA versus 8.0 for placebo) and at all time points assessed throughout the day (P < .01). Children taking DAYTRANA also attempted more math questions on the Permanent Product Measure of Performance (PERMP) scale than those taking placebo (114 versus 87, respectively) and completed more math problems correctly than did those taking placebo (110 versus 81, respectively).
In the phase III naturalistic trial with 270 participants, investigators found that DAYTRANA worn for nine hours reduced the children's overall symptoms of ADHD, compared to a placebo (P < .0001), as measured by scores on the ADHD Rating Scale (ADHD-RS-IV), in which higher scores reflect greater impairment. By the study's end, mean ADHD-RS-IV scores declined 56% (24.2 points) from baseline for children treated with DAYTRANA versus a decline of 24% (10.3 points) for those treated with placebo (P < .0001). ADHD-RS-IV assesses 18 individual symptoms of ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision®, a publication of the American Psychiatric Association.
In both the phase II and phase III studies, DAYTRANA was generally well tolerated during both the dose optimization and double-blind phases. Adverse events typically were mild to moderate, resolved with continued therapy and were consistent with known effects of methylphenidate.
Important Safety Information
DAYTRANA was generally well tolerated in clinical studies. As with other products containing methylphenidate (the active ingredient in DAYTRANA), common side effects reported with DAYTRANA were decreased appetite, insomnia, nausea, vomiting, weight loss, tics, and affect lability (mood swings). Abuse of methylphenidate may lead to dependence.
Parents or caregivers should tell the child's physician about any heart conditions their child or family members may have. Also parents and caregivers should tell the doctor if their child has a history of high blood pressure, problems with alcohol or drugs, depression, bipolar disorder, abnormal thoughts/behaviors, visual disturbances, or seizures. Inform the doctor immediately if the child develops symptoms that suggest heart problems, such as chest pain or fainting. Aggression, new abnormal thoughts/behaviors, mania, and growth suppression have been associated with use of drugs of this type. Methylphenidate should not be taken by children with significant agitation; glaucoma; tics, family history or diagnosis of Tourette's syndrome; or current/recent use of MAO inhibitors (a type of antidepressant). DAYTRANA should not be used by children allergic to methylphenidate or other ingredients in DAYTRANA.
DAYTRANA should be applied daily to clean, dry skin, which is free of any cuts or irritation. Skin irritation or allergic skin rash may occur.
For Full Prescribing Information on DAYTRANA system, please visit www.ADHDSupport.com or www.DAYTRANA.com or call Shire Medical Affairs at 1-800-828-2088, option 4.
Shire's strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on central nervous system, gastrointestinal, general products and human genetic therapies. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company's website: www.shire.com.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire plc's results could be materially affected. The risks and uncertainties include, but are not limited to: risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to, the impact of those on Shire plc's Attention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but not limited to, legal challenges relating to Shire plc's ADHD franchise; government regulation and approval, including but not limited to the expected product approval dates of SPD503 (ADHD), SPD465 (ADHD), MESAVANCE(TM) (SPD476) (ulcerative colitis), Elaprase(TM) (I2S) (Hunter syndrome) and NRP104 (ADHD), including its scheduling classification by the Drug Enforcement Administration in the United States; Shire plc's ability to benefit from the acquisition of Transkaryotic Therapies Inc.; Shire plc's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire plc's and its predecessor registrant Shire Pharmaceuticals Group plc's filings with the US Securities and Exchange Commission, including Shire plc's Annual Report on Form 10-K for the year ended December 31, 2005.
 The change from baseline to study endpoint.
Daytrana(TM), Mesavance(TM) and Elaprase(TM) are trademarks of companies within the Shire group.
DOT Matrix(tm) is a trademark of Noven Pharmaceuticals, Inc.
Diagnostic and Statistical Manual of Mental Disorders is a registered trademark of the American Psychiatric Association.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.